z-logo
open-access-imgOpen Access
Efficiency of Ipratropium Bromide and Albuterol Deposition in the Lung Delivered via a Soft Mist Inhaler or Chlorofluorocarbon Metered‐Dose Inhaler
Author(s) -
MacGregor TR,
ZuWallack R,
Rubano V,
Castles MA,
Dewberry H,
Ghafouri M,
Wood CC
Publication year - 2016
Publication title -
clinical and translational science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.303
H-Index - 44
eISSN - 1752-8062
pISSN - 1752-8054
DOI - 10.1111/cts.12387
Subject(s) - ipratropium bromide , chlorofluorocarbon , inhaler , metered dose inhaler , ipratropium , dry powder inhaler , bronchodilator , medicine , chemistry , anesthesia , asthma , organic chemistry
The propellant‐free Combivent Respimat Soft Mist Inhaler (CVT‐R) was developed to replace the chlorofluorocarbon‐propelled Combivent metered‐dose inhaler (CVT‐MDI). This steady‐state pharmacokinetic (PK) substudy evaluated drug lung‐delivery efficiency, using data from two phase III safety and efficacy trials. PK parameters were obtained from well‐controlled population PK analyses. Area under the plasma concentration–time curve (AUC), maximum observed plasma concentration (C max ), and minimum observed plasma concentration (C min ) showed systemic exposure to ipratropium bromide and albuterol delivered via the CVT‐R was proportional to ex‐mouthpiece delivered dose. Although the labeled dose of ipratropium bromide in the CVT‐R was half that in the CVT‐MDI, the systemic exposure was comparable. No PK interaction for the ipratropium bromide and albuterol Respimat drug components was demonstrated. Ipratropium bromide alone resulted in similar exposure to the combination of ipratropium bromide and albuterol. These results show that CVT‐R delivers drug more efficiently to the lung than CVT‐MDI.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here